Sirona Dx offers a menu of Immuno-Oncology expression profiling assays to explore tumor immunobiology and identify new biomarkers. Our scientific team can guide you the platforms and assays that best meet your requirements.
Advanta IO Gene Expression Assay
A powerful immuno-oncology focused assay we developed in collaboration with Fluidigm and launched in 2017.
Comprises 170 genes including markers for:
- Immune cell identification
- Immune and cancer cell function
- Immune regulation and cell fate
- Checkpoint therapy response
Optimized for FFPE and fresh frozen tumor samples.
Uses TaqMan® chemistry to sensitively measure gene expression, with five reference genes serving as analysis controls. Runs on the Biomark HD platform with Fluidigm microfluidics technology and requires as little as 10ng RNA.
Easily customizable. Add up to 17 new assays or exchange gene assays within the panel.
NanoString nCounter® Panels
With the NanoString nCounter® system we can multiplex up to 800 targets in a single reaction with no amplification. The system counts targets digitally, delivering robust performance and reproducibility. A more cost-effective approach compared to RNA-Seq. Validation services available.
PanCancer IO 360
750 cancer-related genes involved in the complex interplay between the tumor, microenvironment and immune response including 20 internal reference controls.
PanCancer Immune Profiling
770 immune profiling genes for the identification of different immune cell types, key checkpoint inhibitors, cancer antigens, genes for measuring the immune response & up to 40 internal reference controls.
Immune Exhaustion Panel
785 genes annotated across 47 pathways covering the mechanisms behind immune exhaustion in T cells, B cells, and NK cells. Includes 12 reference genes and the 18-gene Tumor Inflammation Signature as well as immune cell typing signatures for quantifying the relative abundance of 14 different immune cell types.
PanCancer Pathways
770 genes for essential cancer pathways including 40 internal reference controls for the human panel & 20 for the mouse panel.
TCR Diversity
119 genes and 10 reference genes that cover all of the T cell receptor (TCR) alpha, beta, gamma, and delta variable regions as well as constant regions and certain T cell and NK cell markers. Can be purchased with a TCR Data Analysis Report within the ROSALIND® Platform that gives a TCR Diversity Score for each sample along with a heatmap and relevant QC metrics.
IO Myeloid Activity
90 genes for the study of myeloid activity in immuno-oncology and 6 reference genes for normalization. The immune response to a tumor is often hampered by a variety of factors, including T-cell anergy and myeloid cell activity. Immunotherapies seek to re-activate the immune system against the tumor by alleviating factors that could prevent immunity. This panel contains genes that profile myeloid suppression of anti-tumor immunity.
Immune Response to Tumors
90 genes for the study of the immune response to tumors and 6 reference genes to be used for normalization. The anti-tumor immune response involves a host of interactions between tumor and immune system. Antigens presented by the tumor or by antigen presenting cells elicit T-cell responses that result in anti-tumor immunity. Additionally, presence of the tumor often elicits an inflammatory response in the microenvironment and thus cytokine release and subsequent downstream pathway activation.
IO Lymphocyte Activity
90 genes for the study of lymphocyte activity in immuno-oncology and 6 reference genes to be used for normalization. The immune response to a tumor is often hampered by a variety of factors, including T-cell anergy and myeloid cell activity. Immunotherapies seek to re-activate the immune system against the tumor by alleviating factors that could prevent immunity. This panel contains genes that profile lymphocyte activation in response to the tumor.
CAR-T Characterization
770 CAR-T related genes plus 10 internal reference controls.
PanCancer Progression
770 genes involved in cancer progression including angiogenesis, extracellular matrix remodeling (ECM), epithelial to mesenchymal transistion (EMT), metastasis including 30 internal reference controls.
Tumor Signaling 360
The nCounter® Tumor Signaling 360 Panel includes 760 genes covering the core pathways and processes of the tumor, tumor micro-environment, and tumor immune response, and 20 internal reference genes for data normalization.
Custom Panels Available
Contact us for custom panel development such as CodeSet Plus, Panel Plus, Elements TagSets, PlexSet and Vantage 3D assays.